Etripamil
Milestone Pharma
['etripamil']
#rapid #aha22
phase 3 study etripamil nasal ca channel block in svt at primary endpoint = psvt
conversion to nsr at 30 min
effective: by 30min 64.3% converted 31.2% placebo
er avoided in pooled analysis:22% placebo 14% etripamil: nnt 13 to avoid er
safe:ae mild 
AssistProfessor #cardiologist #SoMe #editor @CircOutcomes & @JournalASEcho #BOD @ase360 #ACCWIC @PittHealthSci #MedHumanities @ColumbiaMed @NUFeinbergMed